ScholarLens Back to search
2009•World Clinical DrugsRequires access

Sunitinib as a molecular targeting agent in renal cell carcinoma

Jie Zhang

Open publisher page 0 citations

Abstract

Renal cell carcinoma(RCC) has three characteristics including high metastatic,prone to relapse and resistant to conventional chemotherapy.And immunotherapy is just efficiency to minority patients.With the development of the molecular biology of RCC,research of targeting therapy of the metastatic RCC has developed quickly.Sunitinib which is one of the molecular targeting agents has made a great efficacy in RCC.But we should pay more attention on its adverse reactions and complications.

About this research paper

What this paper is about

Renal cell carcinoma(RCC) has three characteristics including high metastatic,prone to relapse and resistant to conventional chemotherapy.And immunotherapy is just efficiency to minority patients.With the development of the molecular biology of RCC,research of targeting therapy of the metastatic RCC has developed quickly.Sunitinib which is one of the molecular targeting agents has made a great efficacy in RCC.But we should pay more attention on its adverse reactions and complications.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Renal cell carcinoma(RCC) has three characteristics including high metastatic,prone to relapse and resistant to conventional chemotherapy.And immunotherapy is just efficiency to minority patients.With the development of the molecular biology of RCC,research of targeting therapy of the metastatic RCC has developed quickly.Sunitinib which is one of the molecular targeting agents has made a great efficacy in RCC.But we should pay more attention on its adverse reactions and complications.

Key concepts: Sunitinib, Medicine, Renal cell carcinoma, Targeted therapy, Immunotherapy, Adverse effect, Oncology, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Sunitinib as a molecular targeting agent in renal cell carcinoma — Research Paper | ScholarLens